Negative Earnings: Analysts predict an EPS of -$0.91 and revenue of approximately$2.1 million.Financial Challenges: Despite a P/E ratio of -4.32, challenges in generating positive cash flow are evident, with an enterprise value to operating cash flow ratio of -4.61.Strong Liquidity: KalVista maintains a current ratio of 5.35, indicating a strong liquidity position to cover short-term liabilities.KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) is a biopharmaceutical company focused on developing small molecule ...